Actualización sobre el manejo de microlitiasis testicular

Abstract

Testicular microlithiasis (TM) is a condition commonly associated with testicular neoplasms and genetic disorders; This pathology is commonly detected in testicular ultrasounds, which does not represent a health risk, so pharmacological treatment in TM is limited. The closest recommendation or solution in case of risk of testicular cancer is chemotherapy, which as initial treatment corresponds to: “BEP (or PEB): bleomycin, etoposide, and cisplatin, EP: etoposide and cisplatin, and VIP: VP-16 (etoposide) or vinblastine plus ifo sphamide, and cisplatin. Objective: To determine the management of testicular microlithiasis at present, through the analysis of scientific evidence in databases of the last 5 years. Methodology: the development of this article will be based on an updated bibliographical review based on information from scientific journals from the PubMed, ScienceDirect, Medline, Medigraphic, Scielo, Springer, NCBI database and other updated scientific journals. Conclusions: Although TM does not present a greater risk to male health, in most cases it is necessary to followup and adequate evaluation in patients with other present pathologies by means of testicular ultrasound and tumor markers. In addition, testicular self-examination allows changes in the size, shape or texture of the testicles to be detected. Pharmacology is currently recommended when additional symptoms appear.